Trial Profile

A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 12 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darovasertib (Primary) ; Siremadlin (Primary)
Indications Uveal melanoma
Focus Adverse reactions; First in man
Sponsors Novartis Pharmaceuticals

Most Recent Events

09 Jan 2023 Results (n=68) assessing toxicity and clinical activity of oral protein kinase C inhibitor LXS196 patients with MUM published in the British Journal of Cancer
10 Jun 2022 Status changed from completed to discontinued. The combination part of the study was terminated early due to business reasons.
18 Mar 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com